☰

Erica B. Schleifman, Ph.D. - Publications

Affiliations: 
2011 Yale University, New Haven, CT 
Area:
Genetics, Molecular Biology, Cell Biology
Tree Info Grants Similar researchers PubMed Report error

28 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Socinski MA, Paul SM, Yun C, Hu S, Shen V, Velcheti V, Mok TS, Gandara DR, Chae YK, Schleifman E, Fabrizio DA, Shames DS, Phan S, Kim ES. Abstract CT194: Exploratory subgroup analysis of atezolizumab (atezo) clinical characteristics in patients (pts) with low circulating tumor DNA (ctDNA) in B-F1RST—a Phase II trial evaluating blood-based tumor mutational burden (bTMB) in NSCLC Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct194  0.313
2018 Li Y, Sun JX, Skoletsky J, Milbury C, Burns C, Yip WK, Dewal N, He J, Tuesdell J, Peters E, Schleifman E, Noe J, Jenkins S, Elvin JA, Otto G, et al. Clinical and analytical validation of an FDA approved comprehensive genomic profiling (CGP) assay incorporating multiple companion diagnostics for targeted and immunotherapies. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii24. PMID 32136529 DOI: 10.1093/Annonc/Mdy269.077  0.344
2018 Clark TA, Chung JH, Kennedy M, Hughes JD, Chennagiri N, Lieber DS, Fendler B, Young L, Zhao M, Coyne M, Breese V, Young G, Donahue A, Pavlick D, Tsiros A, ... ... Schleifman E, et al. Analytical validation of a hybrid capture-based next-generation sequencing clinical assay for genomic profiling of cell-free circulating tumor DNA. The Journal of Molecular Diagnostics : Jmd. PMID 29936259 DOI: 10.1016/J.Jmoldx.2018.05.004  0.392
2018 Lieber DS, White E, Silterra J, Zhong S, Brennan T, Coyne M, Kennedy M, Gandara DR, Kowanetz M, Paul SM, Schleifman E, Li Y, Rittmeyer A, Fehrenbacher L, Amler L, et al. Abstract A41: Analytic validation and clinical feasibility of a next-generation sequencing assay to assess tumor mutational burden from blood (bTMB) as a biomarker for anti-PD-L1 response in NSCLC Cancer Immunology Research. 6. DOI: 10.1158/2326-6074.Tumimm17-A41  0.358
2018 Fabrizio D, Lieber D, Malboeuf C, Silterra J, White E, Coyne M, Brennan T, Ma J, Kennedy M, Schleifman E, Paul S, Li Y, Shames D, Cummings C, Peters E, et al. Abstract 5706: A blood-based next-generation sequencing assay to determine tumor mutational burden (bTMB) is associated with benefit to an anti-PD-L1 inhibitor, atezolizumab Cancer Research. 78: 5706-5706. DOI: 10.1158/1538-7445.Am2018-5706  0.341
2018 Sun JX, Li Y, Milbury C, Skoletsky J, Burns C, Yip W, Luo J, Dewal N, Johnson A, Gowen K, Tong J, He Y, He J, Ma P, White J, ... ... Schleifman E, et al. Abstract 4757: A clinically validated comprehensive companion diagnostic platform for care of patients with advanced cancer Cancer Research. 78: 4757-4757. DOI: 10.1158/1538-7445.Am2018-4757  0.396
2017 Spoerke J, Schleifman E, Clark T, Young G, Nahas M, Kennedy M, Young L, Chmielecki J, Otto G, Lipson D, Wilson T, Gendreau S, Lackner. Abstract P6-07-08: The complete spectrum ofESR1mutations from 7590 breast cancer tumor samples Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P6-07-08  0.328
2017 Fabrizio D, Malboeuf C, Lieber D, Zhong S, He J, White E, Coyne M, Silterra J, Brennan T, Ma J, Kennedy M, Schleifman E, Paul S, Li Y, Shames D, et al. Analytic validation of a next generation sequencing assay to identify tumor mutational burden from blood (bTMB) to support investigation of an anti-PD-L1 agent, atezolizumab, in a first line non-small cell lung cancer trial (BFAST) Annals of Oncology. 28: v27. DOI: 10.1093/Annonc/Mdx363.018  0.302
2016 Stephens P, Clark TA, Kennedy M, He J, Young G, Zhao M, Coyne M, Breese G, Ross JS, Young L, Zhong S, Bailey M, Fendler B, Miller VA, Schleifman E, et al. Analytic validation of a clinical circulating tumor DNA assay for patients with solid tumors. Journal of Clinical Oncology. 34: e23049-e23049. DOI: 10.1200/Jco.2016.34.15_Suppl.E23049  0.336
2016 Clark TA, Kennedy M, He J, Young G, Zhao M, Coyne M, Breese V, Young L, Zhong S, Bailey M, Fendler B, Schleifman E, Peters E, Stephens PJ, Otto GA, et al. Abstract 3965: Rigorous validation of a clinical circulating tumor DNA assay for cancer molecular profiling Cancer Research. 76: 3965-3965. DOI: 10.1158/1538-7445.Am2016-3965  0.377
2016 Stephens PJ, Clark T, Kennedy M, He J, Young G, Zhao M, Coyne M, Breese V, Young L, Zhong S, Bailey M, Fendler B, Miller VA, Schleifman E, Peters E, et al. Analytic validation of a clinical circulating tumor DNA assay for patients with solid tumors Annals of Oncology. 27. DOI: 10.1093/Annonc/Mdw380.01  0.313
2015 Schleifman EB, Motlhabi M, Cummings C, Nakamura R, Bosch L, Patel R, Do A, Watson A, Sandmann T, Darbonne W, McCaffery I, Peters E, Raja R. Abstract 4901: Comparison of gene expression platforms: RNA-Seq, Fluidigm, and Nanostring Cancer Research. 75: 4901-4901. DOI: 10.1158/1538-7445.Am2015-4901  0.305
2014 Wilson TR, Xiao Y, Spoerke JM, Fridlyand J, Koeppen H, Fuentes E, Huw LY, Abbas I, Gower A, Schleifman EB, Desai R, Fu L, Sumiyoshi T, O'Shaughnessy JA, Hampton GM, et al. Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples. Breast Cancer Research and Treatment. 148: 315-25. PMID 25338319 DOI: 10.1007/S10549-014-3163-8  0.308
2014 Zhang L, Chen L, Sah S, Latham GJ, Patel R, Song Q, Koeppen H, Tam R, Schleifman E, Mashhedi H, Chalasani S, Fu L, Sumiyoshi T, Raja R, Forrest W, et al. Profiling cancer gene mutations in clinical formalin-fixed, paraffin-embedded colorectal tumor specimens using targeted next-generation sequencing. The Oncologist. 19: 336-43. PMID 24664487 DOI: 10.1634/Theoncologist.2013-0180  0.379
2014 Schleifman EB, Tam R, Patel R, Tsan A, Sumiyoshi T, Fu L, Desai R, Schoenbrunner N, Myers TW, Bauer K, Smith E, Raja R. Next generation MUT-MAP, a high-sensitivity high-throughput microfluidics chip-based mutation analysis panel. Plos One. 9: e90761. PMID 24658394 DOI: 10.1371/Journal.Pone.0090761  0.381
2014 Schleifman EB, Desai R, Spoerke JM, Xiao Y, Wong C, Abbas I, O'Brien C, Patel R, Sumiyoshi T, Fu L, Tam RN, Koeppen H, Wilson TR, Raja R, Hampton GM, et al. Targeted biomarker profiling of matched primary and metastatic estrogen receptor positive breast cancers. Plos One. 9: e88401. PMID 24520381 DOI: 10.1371/Journal.Pone.0088401  0.321
2014 Schleifman EB, Glazer PM. Peptide nucleic acid-mediated recombination for targeted genomic repair and modification. Methods in Molecular Biology (Clifton, N.J.). 1050: 207-22. PMID 24297362 DOI: 10.1007/978-1-62703-553-8_17  0.681
2013 Schleifman EB, McNeer NA, Jackson A, Yamtich J, Brehm MA, Shultz LD, Greiner DL, Kumar P, Saltzman WM, Glazer PM. Site-specific Genome Editing in PBMCs With PLGA Nanoparticle-delivered PNAs Confers HIV-1 Resistance in Humanized Mice. Molecular Therapy. Nucleic Acids. 2: e135. PMID 24253260 DOI: 10.1038/Mtna.2013.59  0.754
2013 McNeer NA, Schleifman EB, Cuthbert A, Brehm M, Jackson A, Cheng C, Anandalingam K, Kumar P, Shultz LD, Greiner DL, Mark Saltzman W, Glazer PM. Systemic delivery of triplex-forming PNA and donor DNA by nanoparticles mediates site-specific genome editing of human hematopoietic cells in vivo. Gene Therapy. 20: 658-69. PMID 23076379 DOI: 10.1038/Gt.2012.82  0.778
2013 Tam RNW, Schleifman E, Huw L, Desai R, Patel R, Raja R. Abstract 4134: Development of MUT-MAP, a high-throughput multi-analyte mutation panel for cancer biomarkers discovery. Cancer Research. 73: 4134-4134. DOI: 10.1158/1538-7445.Am2013-4134  0.398
2013 Do AD, Sumiyoshi T, Wang Y, Schleifman E, Xiao Y, Klughammer B, Wong CV, Abbas I, Fu L, Amler LC, Raja R, Shames DS. Abstract 3500: Analysis of the prevalence and prognostic significance of 92 endpoints using high throughput multiplexed qPCR In archival tissue from multiple NSCLC trials. Cancer Research. 73: 3500-3500. DOI: 10.1158/1538-7445.Am2013-3500  0.347
2013 Schleifman EB, Desai RM, Spoerke J, Wong CV, Abbas I, O'Brien C, Hampton G, Wilson T, Koeppen H, Patel R, Sumiyoshi T, Fu L, Tam R, Raja R, Lackner M. Abstract 3462: High-throughput qRT-PCR expression profiling of estrogen receptor positive breast tumors. Cancer Research. 73: 3462-3462. DOI: 10.1158/1538-7445.Am2013-3462  0.338
2013 Kim D, Choi Y, French D, Patel R, Fu L, Wong C, Abbas I, Tam R, Schleifman E, Sumiyoshi T, Faarborg A, Yauch B, Hampton G, Amler L, Raja R, et al. Abstract 1203: Molecular stratification of bladder cancer reveals distinct subtypes associated with unique clinical behaviors. Cancer Research. 73: 1203-1203. DOI: 10.1158/1538-7445.Am2013-1203  0.321
2011 Schleifman EB, Bindra R, Leif J, del Campo J, Rogers FA, Uchil P, Kutsch O, Shultz LD, Kumar P, Greiner DL, Glazer PM. Targeted disruption of the CCR5 gene in human hematopoietic stem cells stimulated by peptide nucleic acids. Chemistry & Biology. 18: 1189-98. PMID 21944757 DOI: 10.1016/J.Chembiol.2011.07.010  0.741
2011 McNeer NA, Schleifman EB, Glazer PM, Saltzman WM. Polymer delivery systems for site-specific genome editing. Journal of Controlled Release : Official Journal of the Controlled Release Society. 155: 312-6. PMID 21620910 DOI: 10.1016/J.Jconrel.2011.05.011  0.763
2011 McNeer NA, Chin JY, Schleifman EB, Fields RJ, Glazer PM, Saltzman WM. Nanoparticles deliver triplex-forming PNAs for site-specific genomic recombination in CD34+ human hematopoietic progenitors. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 172-80. PMID 20859257 DOI: 10.1038/Mt.2010.200  0.7
2008 Schleifman EB, Chin JY, Glazer PM. Triplex-mediated gene modification. Methods in Molecular Biology (Clifton, N.J.). 435: 175-90. PMID 18370076 DOI: 10.1007/978-1-59745-232-8_13  0.749
2007 Chin JY, Schleifman EB, Glazer PM. Repair and recombination induced by triple helix DNA. Frontiers in Bioscience : a Journal and Virtual Library. 12: 4288-97. PMID 17485375 DOI: 10.2741/2388  0.748
Show low-probability matches.